Shenzhen Neptunus Bioengineering Co Ltd

(a) Capital structure and liquidity are characterized by extreme leverage and tight liquidity buffers. The company reports total liabilities of 25.1 billion CNY against total equity of 1.2 billion CNY, resulting in a debt-to-equity ratio of 11.22. Long-term debt stands at 13.8 billion CNY, significantly exceeding the market capitalization of 4.9 billion CNY. The current ratio is 1.0, indicating that current assets barely cover current liabilities, which aligns with the medium liquidity risk assessment. Operating cash flow is positive at 104.4 million CNY, but free cash flow is negative at -982.1 million CNY, driven by capital expenditures of 127.1 million CNY.

(b) Profitability is negative across all major metrics, reflecting a loss-making position. The company reports a net income of -563.1 million CNY and an operating income of -505.7 million CNY on revenues of 26.7 billion CNY. Return on equity is -45.88% and return on assets is -2.14%, indicating inefficient use of capital. The gross profit of 2.5 billion CNY suggests a gross margin of approximately 9.3%, which is thin for a health care provider, though specific cohort medians are not provided for direct comparison. The negative EV/EBITDA of -36.89 further underscores the lack of earnings power.